Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Neuroblastoma Treatment Market: By Diagnostics, By Drugs, By Treatment, and Geography
Neuroblastoma Treatment Market size was valued at US$ 542 billion in 2023 and is poised to grow at a CAGR of 3.6% from 2024-30. The global market provides a detailed overview and that can be segmented by diagnostics, by drugs, and by treatment. By diagnostics, the global neuroblastoma treatment market has been segmented into MIBG Scan, Imaging, Urine Analysis, and Biopsy. The Imaging segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. MIBG scan segment is also growing at a faster rate. Based on drugs, the global neuroblastoma treatment market is segmented Crizotinib, Doxorubicin Hydrochloride, Cyclophosphamide, Vincristine Sulfate, and Others.
Among these, the Crizotinib segment is expected to have the fastest-growing market during the forecast period 2022-2028. It is attributed to the efficiency of the drug and high demand in the market. Also, Hydrochloride drugs has high demand in the global market and is expected to grow at a significant CAGR in the upcoming forecasted years. Based on treatment, the global neuroblastoma treatment market is segmented into Surgery, Chemotherapy, High-Dose Chemotherapy with Stem Cells Support, Monoclonal Antibody Treatment, Radiotherapy, and Others. The Surgery segment accounts for the largest share in 2021.
Chemotherapy segment is the second-largest share during the forecast period 2022-2028 according to precision business insights. Although, high risk and side effects associated with Chemotherapy is restraining the growth of this segment at a significant rate. Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global neuroblastoma treatment products.
Study Period
2024-2030Base Year
2023CAGR
3.6%Largest Market
North AmericaFastest Growing Market
Europe
Increasing prevalence of neuroblastoma, rising healthcare expenses, and a greater number of awareness programs on neuroblastoma are anticipated to propel the market growth over the forecast years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 542 billion |
Market CAGR |
3.6% |
By Diagnostics |
|
By Drugs |
|
By Treatment |
|
Download Free Sample Report
The global neuroblastoma treatment market size was valued at US$ 542 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024-2030.
Investment in research and development sector to invent new therapies and treatment are the main strategy of the global market players.
High cost and side effects associated with treatment options may hamper the global market growth.
Key Market Players